Improving outcomes in T2D with SGLT-2 inhibitors: The time to act is now

01 Sep 2021
At the recent EMPIRE (Evidence on the Management Pathway In T2D with CVD Risk and REnal Impairment) Summit organised by Boehringer Ingelheim, several eminent speakers shared the latest updates on T2D management and the need for early treatment intensification to optimise patient outcomes.
Editor's Recommendations